Skip Navigation


Brain Advance Access originally published online on December 2, 2006
Brain 2007 130(2):502-513; doi:10.1093/brain/awl330
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
130/2/502    most recent
awl330v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (8)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Mousa, S. A.
Right arrow Articles by Schäfer, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mousa, S. A.
Right arrow Articles by Schäfer, M.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author (2006). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

Nerve growth factor governs the enhanced ability of opioids to suppress inflammatory pain

Shaaban A. Mousa1, Bopaiah P. Cheppudira1, Mohammed Shaqura1, Oliver Fischer1, Julia Hofmann2, Rainer Hellweg2 and Michael Schäfer1

1 Klinik für Anaesthesiologie und Operative Intensivmedizin, Charité-Universitätsmedizin Berlin Campus Benjamin Franklin, Berlin, Germany 2 Klinik und Hochschulambulanz für Psychiatrie und Psychotherapie, Charité-Universitätsmedizin Berlin Campus Benjamin Franklin, Berlin, Germany

Correspondence to: Prof. Michael Schäfer, MD, Klinik für Anaesthesiologie und Operative Intensivmedizin, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, D-12200 Berlin, Germany, Hindenburgdamm 30, D-12200 Berlin, Germany E-mail: micha.schaefer{at}charite.de

Nerve growth factor (NGF) regulates sensory neuron phenotype by elevated expression of ion channels and receptors contributing to pain. Peripheral opioid antinociception is dependent on sensory neuron µ opioid receptor (MOR) expression, coupling and efficacy. This study investigates the role of NGF in the upregulation of the number and efficacy of sensory MORs rendering sites of painful inflammation more susceptible to opioids. We identified co-localization of MOR with calcitonin gene-related peptides (CGRP) and with the NGF receptors tyrosine receptor kinase (TrkA) and p75NTR within rat dorsal root ganglia (DRG). We showed that unilateral hind paw inflammation induced with Freund's complete adjuvant (FCA) or intraplantar (i.pl.) NGF increased NGF's retrograde transport and MOR expression in TrkA positive DRG which was prevented by the disruption of this NGF transport. MOR upregulation in DRG was followed by enhanced axonal MOR transport towards peripheral nerve terminals and subsequent increase of MOR-ir nerve fibres within skin. Furthermore, peripheral antinociception elicited by i.pl. fentanyl was naloxone reversible and potentiated exclusively in inflamed and NGF-treated paws. Both FCA- and NGF-induced effects occurring through DRG to peripheral nerve fibres and the potentiation of antinociception were abrogated by NGF neutralization. Therefore, our results suggest that NGF not only contributes to inflammatory pain but also governs the upregulation in the number and efficacy of sensory neuron MOR, resulting in enhanced opioid susceptibility towards better pain control. This suggests the potential to overcome the unresponsiveness to opioids of certain neuropathic pain states.

Key Words: opioid receptors; sensory neuron; nerve growth factor; pain, antinociception

Abbreviations: CGRP, calcitonin gene-related peptides; DRG, dorsal root ganglia; FCA, Freund's complete adjuvant; i.pl., intraplantar; MOR, µ-opioid receptor; NGF, nerve growth factor; TrkA, tyrosine receptor kinase

Received April 13, 2006. Revised August 29, 2006. Accepted October 10, 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.